Literature DB >> 29924878

Chiari I Malformation and Basilar Invagination in Fibrous Dysplasia: Prevalence, Mechanisms, and Clinical Implications.

Kristen S Pan1, John D Heiss2, Sydney M Brown1, Michael T Collins1, Alison M Boyce1.   

Abstract

Fibrous dysplasia (FD) is a mosaic disorder of benign fibro-osseous lesions, which may be associated with extraskeletal features as part of McCune-Albright syndrome (MAS). Cranial base abnormalities, including Chiari I malformation (CM1), in which the cerebellum extends below the foramen magnum, and secondary basilar invagination (BI), in which the odontoid prolapses into the posterior cranial fossa, are potentially serious complications of metabolic bone disorders. The purpose of this study was to determine the prevalence, natural history, and risk factors for CM1 and BI in patients with FD/MAS, and to determine mechanisms of cranial base deformities. Clinical and radiographic data from subjects in an FD/MAS natural history study were evaluated and compared to normal controls. In 158 patients with craniofacial FD, 10 (6.3%) cases of CM1 and 12 (7.6%) cases of BI were diagnosed. No cranial base abnormalities were identified in 10 control subjects. Craniomorphometric and volumetric analyses identified cranial constriction and cranial settling as the primary mechanisms of cranial base abnormalities, whereas intracranial hypertension was a contributing factor in a minority of subjects. Longitudinal analyses found progression of odontoid position with age, but no progression of tonsillar position. No endocrinopathies were associated with CM1. MAS endocrinopathies associated with BI included hyperthyroidism (odds ratio [OR] 12.0; 95% confidence interval [CI], 2.9 to 55.6; p < 0.01), precocious puberty (OR 5.6; 95% CI, 1.2 to 26.0; p < 0.05), and hypophosphatemia (OR 7.7; 95% CI, 1.9 to 27.0; p < 0.01). Scoliosis was associated with both CM1 (OR 4.8; 95% CI, 1.1 to 22.8; p < 0.05) and BI (OR = infinity; 95% CI, 4.7 to infinity; p < 0.01). This study successfully characterized cranial base abnormalities in FD/MAS and the pathophysiological connection between them. These findings support routine screening for cranial base abnormalities in patients with craniofacial FD, as well as aggressive management of contributory risk factors.
© 2018 American Society for Bone and Mineral Research. © 2018 American Society for Bone and Mineral Research.

Entities:  

Keywords:  BONE INTERACTORS; BONE-BRAIN-NERVOUS SYSTEM INTERACTIONS; DISEASES AND DISORDERS OF/RELATED TO BONE; OSTEOMALACIA AND RICKETS; SYSTEMS BIOLOGY

Mesh:

Year:  2018        PMID: 29924878      PMCID: PMC6218312          DOI: 10.1002/jbmr.3531

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  47 in total

1.  Occipital fibrous dysplasia tonsillar herniation and cervical syringomyelia.

Authors:  M J Chandy
Journal:  Br J Neurosurg       Date:  1999-04       Impact factor: 1.596

2.  Chiari I malformation redefined: clinical and radiographic findings for 364 symptomatic patients.

Authors:  T H Milhorat; M W Chou; E M Trinidad; R W Kula; M Mandell; C Wolpert; M C Speer
Journal:  Neurosurgery       Date:  1999-05       Impact factor: 4.654

3.  Age-related changes in the relative growth of the posterior fossa.

Authors:  G B Schaefer; J N Thompson; J B Bodensteiner; M Gingold; M Wilson; D Wilson
Journal:  J Child Neurol       Date:  1991-01       Impact factor: 1.987

4.  CT evaluation of Chamberlain's, McGregor's, and McRae's skull-base lines.

Authors:  C G Cronin; D G Lohan; J N Mhuircheartigh; C P Meehan; J Murphy; C Roche
Journal:  Clin Radiol       Date:  2008-10-14       Impact factor: 2.350

5.  Basilar invagination in osteogenesis imperfecta and related osteochondrodysplasias: medical and surgical management.

Authors:  P D Sawin; A H Menezes
Journal:  J Neurosurg       Date:  1997-06       Impact factor: 5.115

Review 6.  Basilar Invagination, Basilar Impression, and Platybasia: Clinical and Imaging Aspects.

Authors:  Nandor K Pinter; Jennifer McVige; Laszlo Mechtler
Journal:  Curr Pain Headache Rep       Date:  2016-08

7.  An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone.

Authors:  Michael T Collins; Harvey Kushner; James C Reynolds; Caroline Chebli; Marilyn H Kelly; Anurag Gupta; Beth Brillante; Arabella I Leet; Mara Riminucci; Pamela Gehron Robey; Paolo Bianco; Shlomo Wientroub; Clara C Chen
Journal:  J Bone Miner Res       Date:  2004-11-16       Impact factor: 6.741

8.  Position of cerebellar tonsils in the normal population and in patients with Chiari malformation: a quantitative approach with MR imaging.

Authors:  A O Aboulezz; K Sartor; C A Geyer; M H Gado
Journal:  J Comput Assist Tomogr       Date:  1985 Nov-Dec       Impact factor: 1.826

Review 9.  McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia.

Authors:  Michael T Collins; Frederick R Singer; Erica Eugster
Journal:  Orphanet J Rare Dis       Date:  2012-05-24       Impact factor: 4.123

10.  The odontoid process invagination in normal subjects, Chiari malformation and Basilar invagination patients: Pathophysiologic correlations with angular craniometry.

Authors:  Jânio A Ferreira; Ricardo V Botelho
Journal:  Surg Neurol Int       Date:  2015-07-08
View more
  12 in total

Review 1.  Fibrous Dysplasia of Bone and McCune-Albright Syndrome: A Bench to Bedside Review.

Authors:  Iris Hartley; Maria Zhadina; Micheal T Collins; Alison M Boyce
Journal:  Calcif Tissue Int       Date:  2019-04-29       Impact factor: 4.333

2.  Long-term imaging course of Chiari malformation type I due to fibrous dysplasia/McCune-Albright syndrome.

Authors:  Kei Sato; Keishi Tsunoda; Takayuki Matsuo
Journal:  Childs Nerv Syst       Date:  2022-07-05       Impact factor: 1.532

3.  Long Bone Fractures in Fibrous Dysplasia/McCune-Albright Syndrome: Prevalence, Natural History, and Risk Factors.

Authors:  Raya E S Geels; Maartje E Meier; Amanda Saikali; Roula Tsonaka; Natasha M Appelman-Dijkstra; Alison M Boyce
Journal:  J Bone Miner Res       Date:  2021-11-17       Impact factor: 6.390

Review 4.  Chiari Malformation (Update on Diagnosis and Treatment).

Authors:  Jared S Rosenblum; I Jonathan Pomeraniec; John D Heiss
Journal:  Neurol Clin       Date:  2022-03-31       Impact factor: 3.787

Review 5.  DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.

Authors:  Luis F de Castro; Diana Ovejero; Alison M Boyce
Journal:  Eur J Endocrinol       Date:  2020-05       Impact factor: 6.664

Review 6.  The Clinical Spectrum of McCune-Albright Syndrome and Its Management.

Authors:  Tiahna Spencer; Kristen S Pan; Michael T Collins; Alison M Boyce
Journal:  Horm Res Paediatr       Date:  2019-12-19       Impact factor: 2.852

7.  Burosumab treatment for fibrous dysplasia.

Authors:  Anne Gladding; Vivian Szymczuk; Bethany A Auble; Alison M Boyce
Journal:  Bone       Date:  2021-05-11       Impact factor: 4.626

Review 8.  Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone.

Authors:  Marlous Rotman; Neveen Agnes Therese Hamdy; Natasha M Appelman-Dijkstra
Journal:  Br J Clin Pharmacol       Date:  2018-12-25       Impact factor: 4.335

Review 9.  Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium.

Authors:  Muhammad Kassim Javaid; Alison Boyce; Natasha Appelman-Dijkstra; Juling Ong; Patrizia Defabianis; Amaka Offiah; Paul Arundel; Nick Shaw; Valter Dal Pos; Ann Underhil; Deanna Portero; Lisa Heral; Anne-Marie Heegaard; Laura Masi; Fergal Monsell; Robert Stanton; Pieter Durk Sander Dijkstra; Maria Luisa Brandi; Roland Chapurlat; Neveen Agnes Therese Hamdy; Michael Terrence Collins
Journal:  Orphanet J Rare Dis       Date:  2019-06-13       Impact factor: 4.123

Review 10.  Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.

Authors:  Alison M Boyce; Michael T Collins
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.